TH-189: A Phase 2 Study of Nivolumab plus Ramucirumab in Patients with Recurrent Advanced Metastatic Non-Small Cell Lung Carcinoma

Brief description of study

This study will involve patients who have been diagnosed with non-small cell lung cancer, regardless of the specific type. These patients should have previously received immunotherapy but their disease has gotten worse after one round of treatment using either immunotherapy alone or a combination of immunotherapy and chemotherapy. Patients will receive two medications called Nivolumab and Ramucirumab. These medications will be given through a vein, and the dose will depend on the patient's body weight. The treatment will be given on the first day and the fifteenth day of each 28-day cycle.

To see how well the treatment is working, patients will have regular check-ups every two cycles. They will undergo a CT scan to see how the disease is responding to the treatment. The check-ups will be done within a week before or after the scheduled date. The treatment will continue until the disease gets worse, the side effects become too severe, or the patient decides to stop the treatment. The patients will be followed up until they pass away to monitor their condition and gather more information.


Clinical Study Identifier: s22-01366
Principal Investigator: Vamsidhar Velcheti.
Other Investigators: Jessica Wang, Elaine Shum, Salman Rafi Punekar, Sally Lau, Joshua K Sabari, David Mendoza, Natalia Cherkassky, Avital Benson, Melissa L Martinez.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.